Antitrust regulation is running off the rails in Europe and the U.S., and their citizens could wind up as collateral damage. The latest example is the European Commission’s order Tuesday to derail gene-sequencing giant Illumina’s acquisition of cancer blood-test startup Grail.

Grail has developed a lab test that can identify more than 50 cancers at early stages with a simple blood draw. Screenings don’t exist for most cancers, so many aren’t caught until they’ve spread and are harder to treat. While Grail’s test can’t catch all cancers, it can detect the 12 deadliest with about 76% accuracy, and its false positives are less than 1%. The tests could save tens of thousands of lives a year if widely adopted.